Literature DB >> 3335948

Intermittent versus long-term tapering prednisolone for initial therapy in children with idiopathic nephrotic syndrome.

N Ueda1, M Chihara, S Kawaguchi, Y Niinomi, T Nonoda, J Matsumoto, M Ohnishi, T Yasaki.   

Abstract

Forty-six children with steroid-responsive nephrotic syndrome were randomly allocated to receive two different prednisolone regimens for initial therapy. Twenty-nine children (group 1) received an intermittent regimen (60 mg/m2/day for 4 weeks, followed by 40/mg/m2/day on 3 days a week for 4 weeks); 17 children (group 2) had a long-term regimen (60 mg/m2/day for 4 weeks, followed by the same dose on alternate days for 4 weeks and the doses tapered by 10 mg/m2, given on alternate days every 4 weeks for 5 months). There was no difference between the two groups in the regimen used to treat relapses, steroid responsiveness, number of patients with relapses, and frequency of toxic reactions to steroids. However, the number of patients with a relapse within 6 months after initial therapy and the number of those with frequent relapses or steroid dependence were significantly higher in group 1 than in group 2 (P less than 0.05 for both). The data indicate that the long-term tapering regimen appears to be both safe and preferable to the intermittent regimen for initial therapy in children with idiopathic nephrotic syndrome.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3335948     DOI: 10.1016/s0022-3476(88)80136-7

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  24 in total

1.  Evidence-based practice guideline for the treatment of CKD.

Authors: 
Journal:  Clin Exp Nephrol       Date:  2009-12       Impact factor: 2.801

2.  Pharmacokinetics of prednisolone in children with nephrosis.

Authors:  P F Miller; C J Bowmer; J Wheeldon; J T Brocklebank
Journal:  Arch Dis Child       Date:  1990-02       Impact factor: 3.791

3.  Low dose prednisolone in nephrotic syndrome.

Authors:  I A Choonara; D Heney; S R Meadow
Journal:  Arch Dis Child       Date:  1989-04       Impact factor: 3.791

Review 4.  Corticosteroid therapy for nephrotic syndrome in children.

Authors:  Deirdre Hahn; Elisabeth M Hodson; Narelle S Willis; Jonathan C Craig
Journal:  Cochrane Database Syst Rev       Date:  2015-03-18

5.  Weight or body surface area dosing of steroids in nephrotic syndrome: is there an outcome difference?

Authors:  Sermin A Saadeh; Rossana Baracco; Amrish Jain; Gaurav Kapur; Tej K Mattoo; Rudolph P Valentini
Journal:  Pediatr Nephrol       Date:  2011-07-16       Impact factor: 3.714

6.  Eight and 12 week courses of cyclophosphamide in nephrotic syndrome.

Authors:  N Ueda; K Kuno; S Ito
Journal:  Arch Dis Child       Date:  1990-10       Impact factor: 3.791

7.  Uncertainty in management of childhood-onset idiopathic nephrotic syndrome: is the long-term prognosis really favorable?

Authors:  Shuichiro Fujinaga; Amane Endo; Yoshiyuki Ohtomo; Yoshikazu Ohtsuka; Toshiaki Shimizu
Journal:  Pediatr Nephrol       Date:  2013-07-09       Impact factor: 3.714

8.  Long versus standard initial steroid therapy for children with the nephrotic syndromeA report from the Southwest Pediatric Nephrology Study Group.

Authors:  Marc B Lande; Christina Gullion; Ronald J Hogg; Bernard Gauthier; Binod Shah; Mary B Leonard; Melvin Bonilla-Felix; Martin Nash; Shane Roy; C Frederic Strife; Gerald Arbus
Journal:  Pediatr Nephrol       Date:  2003-03-21       Impact factor: 3.714

9.  Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft für Pädiatrische Nephrologie.

Authors:  J H Ehrich; J Brodehl
Journal:  Eur J Pediatr       Date:  1993-04       Impact factor: 3.183

10.  Two-year outcome of the ISKDC regimen and frequent-relapsing risk in children with idiopathic nephrotic syndrome.

Authors:  Koichi Nakanishi; Kazumoto Iijima; Kenji Ishikura; Hiroshi Hataya; Hitoshi Nakazato; Satoshi Sasaki; Masataka Honda; Norishige Yoshikawa
Journal:  Clin J Am Soc Nephrol       Date:  2013-01-31       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.